Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

Vertex PharmaceuticalsVRTX

Biotechnology · Boston, Massachusetts · In the S&P 500
High qualityPricier than peers
$558.88+3.50%After hours: $554.00 (−0.87%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 34.0% over 1 year
Vertex Pharmaceuticals over 1 yearDaily close, $, to 30 Oct 2026
$450$500Nov2026MarMayJulSep$558.88$500NovMarJul$558.88
Source: Nasdaq daily closes
Market value$142B
Price to earnings32.5x
Forward P/E29.3x
Dividend yield–
Year to date+23.3%
One year+34.0%
Next earningsMon 2 Nov, after the close
SectorHealth Care
52-week range (closes)
$409.47$558.88

Quality and valuation

How Vertex Pharmaceuticals compares with other health care stocks. A description, not a recommendation.

Vertex Pharmaceuticals and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Vertex Pharmaceuticals trades at 29.3 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +10.2% vs +8.1%
  • Keeps more of each sale (gross margin): 86.0% vs 65.0%
  • More profitable (operating margin): 38.0% vs 13.3%
  • Turns more of its sales into cash: 30.2% vs 15.9%
VRTX trades at 29.3x forward earnings, above the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Vertex Pharmaceuticals's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 12.5% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$1bn$2bn$3bnQ3 ’24Q1 ’25Q3 ’25$3.3bnQ2 ’26$0bn$2bnQ3 ’24Q1 ’25Q3 ’25$3.3bnQ2 ’26
Source: SEC filings
Growth sped up to +12.5% last quarterRevenue growth, year on year, %
0%5%10%15%Q3 ’24Q1 ’25Q3 ’2512.5%Q2 ’260%10%Q3 ’24Q1 ’25Q3 ’2512.5%Q2 ’26
Source: SEC filings
Operating margin was 37.4% last quarterOperating income as a share of revenue, %
0%20%40%Q3 ’24Q1 ’25Q3 ’2537.4%Q2 ’260%20%40%Q3 ’24Q1 ’25Q3 ’2537.4%Q2 ’26
Source: SEC filings
Free cash flow was $3.8 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$1.0bnQ2 ’26$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$1.0bnQ2 ’26
Source: SEC filings
Last 12 monthsVRTXSector median
Revenue growth+10.2%+8.1%
Gross margin86.0%65.0%
Operating margin38.0%13.3%
Free cash flow margin30.2%15.9%
Price to earnings32.5x30.2x

Stories on Vertex Pharmaceuticals

We haven't written about Vertex Pharmaceuticals yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
AMGNAmgen$466.01+1.15%+42.4%$252B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
MRNAModerna$221.72−0.47%+651.8%$88.52B
BIIBBiogen$253.62+1.59%+44.1%$37.49B
INCYIncyte$120.39+3.07%+21.9%$24.40B